2020 Feb;19(2):157-169. doi: 10.1016/S1474-4422(19)30153-X. Name must be less than 100 characters 2020 Feb 26;2(2):CD011961. Lacro, Jonathan Unable to load your collection due to an error Donepezil (Aricept) has potential benefit in delaying risk of progression to Alzheimer’s disease in the first year of treatment, but this benefit is not seen at 3 years. and Clipboard, Search History, and several other advanced features are temporarily unavailable.
Holmes, Clive
Treatment of DLB patients with donepezil for 12 weeks most commonly improved hallucinations, and sometimes improved cognition and overall function. Grace, Janet B. Brun, Arne Jaros, Evelyn
* Views captured on Cambridge Core between
.
2000. Johnson, Mary Donepezil may lead to behavioral worsening through its mild activation and alerting properties. Perry, Robert Some people taking donepezil have improved mental function, while others may have unchanged or even worsening mental function. RESULTS: Donepezil was well tolerated and most adverse events were mild. O'Brien, J. Friedman, Joseph H. Anand, Ravi Results: The groups did not differ on most variables at baseline or at six months; however, the donepezil group had greater worsening on the FTD Inventory. McKeith, Ian G Grace, Janet Wesnes, Keith doi: 10.1002/14651858.CD006504.pub2.Nervenarzt. Piggott, Margaret and 2012 Mar 14;(3):CD006504. COVID-19 is an emerging, rapidly evolving situation.
Londos, Elisabet The authors urge great caution in discontinuing treatment with acetylcholinesterase inhibitors such as donepezil. This condition will progress over time, even in people who take donepezil. O'Brien, John T Ballard, Clive 1999. Samuel, William Byrne, E. Jane Free PMC article Severe worsening of parkinsonism in Lewy body dementia due to donepezil. Fernandez, Hubert H. doi: 10.1097/01.JGP.0000231744.69631.33. 2000. Treatment with donepezil was sometimes associated with worse parkinsonism. and Important Information. Cicin-Sain, Ana 2016 Oct;14(4):448-464. doi: 10.1176/appi.focus.20160018. McKeith, Ian G. Passant, Ulla There was no worsening of PD symptoms as measured by the total or …
Clipboard, Search History, and several other advanced features are temporarily unavailable.
McKeith, Ian G. We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Galasko, Douglas The mean observation period was 12 (range 8 to 24) weeks. The primary outcome measure was the Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAScog). and Stevens, Timothy McClure, Fauzia Simjee HighWire Cicin-Sain, Ana Jeste, Dilip V.
HighWire Grace, Janet McClure, Fauzia Simjee 2003 Nov 25;61(10):1452. doi: 10.1212/01.wnl.0000094201.80888.da.Rosenbloom MH, Finley R, Scheinman MM, Feldman MD, Miller BL, Rabinovici GD.Alzheimer Dis Assoc Disord. Del Ser, Teodoro O'Brien, John T and Ballard, Clive Please enable it to take advantage of the complete set of features! 2010 Apr-Jun;24(2):209-11. doi: 10.1097/WAD.0b013e3181b7642b.Intern Med. Anand, Ravi Not only was there no improvement of the somatic symptoms after discontinuation of donepezil, but there was also a worsening of the dementia symptoms, culminating in delirium. Holmes, Clive Function was improved or maintained in six of nine patients and fluctuated in two of nine.
2006 Apr;60(2):190-5. doi: 10.1111/j.1440-1819.2006.01485.x.Expert Rev Neurother.